US5149538A
(en)
*
|
1991-06-14 |
1992-09-22 |
Warner-Lambert Company |
Misuse-resistive transdermal opioid dosage form
|
DE4423850A1
(de)
*
|
1994-07-07 |
1996-01-11 |
Labtec Gmbh |
Transdermales therapeutisches System zur Applikation von Naloxon
|
US5656416A
(en)
*
|
1994-12-22 |
1997-08-12 |
Eastman Kodak Company |
Photographic processing composition and method using organic catalyst for peroxide bleaching agent
|
US6284266B1
(en)
*
|
1995-07-28 |
2001-09-04 |
Zars, Inc. |
Methods and apparatus for improved administration of fentanyl and sufentanil
|
WO1997033566A2
(en)
*
|
1996-03-12 |
1997-09-18 |
Alza Corporation |
Composition and dosage form comprising opioid antagonist
|
US5968547A
(en)
|
1997-02-24 |
1999-10-19 |
Euro-Celtique, S.A. |
Method of providing sustained analgesia with buprenorphine
|
GB9707934D0
(en)
*
|
1997-04-18 |
1997-06-04 |
Danbiosyst Uk |
Improved delivery of drugs to mucosal surfaces
|
US7011843B2
(en)
*
|
1997-10-01 |
2006-03-14 |
Lts Lohmann-Therapie Systeme Ag |
Method for protecting a human being against health impairment by ingestion of a transdermal therapeutic system
|
DE19743484C1
(de)
*
|
1997-10-01 |
1999-01-28 |
Lohmann Therapie Syst Lts |
Transdermales therapeutisches System mit Schutz vor oraler Applikation und Verfahren zum Schutz einer Person vor Kontamination infolge unzulässiger oraler Applikation toxischer Inhaltsstoffe eines transdermalen therapeutischen Systems
|
US6375957B1
(en)
|
1997-12-22 |
2002-04-23 |
Euro-Celtique, S.A. |
Opioid agonist/opioid antagonist/acetaminophen combinations
|
KR100417490B1
(ko)
|
1997-12-22 |
2004-02-05 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 제형의 남용을 방지하는 방법
|
DK1685839T3
(da)
|
1997-12-22 |
2013-06-24 |
Euro Celtique Sa |
Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
|
DE19960154A1
(de)
*
|
1999-12-14 |
2001-07-12 |
Lohmann Therapie Syst Lts |
Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie
|
EP2092936B1
(en)
|
2000-02-08 |
2013-03-20 |
Euro-Celtique S.A. |
Tamper-resistant oral opioid agonist formulations
|
US6716449B2
(en)
|
2000-02-08 |
2004-04-06 |
Euro-Celtique S.A. |
Controlled-release compositions containing opioid agonist and antagonist
|
US20020119187A1
(en)
*
|
2000-09-29 |
2002-08-29 |
Cantor Adam S. |
Composition for the transdermal delivery of fentanyl
|
GB0026137D0
(en)
*
|
2000-10-25 |
2000-12-13 |
Euro Celtique Sa |
Transdermal dosage form
|
WO2002085268A1
(en)
*
|
2001-04-23 |
2002-10-31 |
Euro-Celtique S.A. |
Disposal system for transdermal dosage form
|
EP2316439B1
(en)
*
|
2001-05-01 |
2015-06-17 |
Euro-Celtique S.A. |
Abuse resistant opioid containing transdermal systems
|
CA2446550C
(en)
|
2001-05-11 |
2012-03-06 |
Endo Pharmaceuticals, Inc. |
Abuse-resistant controlled-release opioid dosage form
|
AU2002303148A1
(en)
*
|
2001-06-29 |
2003-03-03 |
Leon J. Lewandowski |
Individualized addiction cessation therapy
|
EP1404332A1
(en)
*
|
2001-07-06 |
2004-04-07 |
Penwest Pharmaceuticals Company |
Methods of making sustained release formulations of oxymorphone related applications
|
BR0205721A
(pt)
*
|
2001-07-06 |
2003-09-30 |
Endo Pharmaceuticals Inc |
Formulações de oximorfona de liberação controlada
|
US8329216B2
(en)
*
|
2001-07-06 |
2012-12-11 |
Endo Pharmaceuticals Inc. |
Oxymorphone controlled release formulations
|
WO2003007802A2
(en)
|
2001-07-18 |
2003-01-30 |
Euro-Celtique, S.A. |
Pharmaceutical combinations of oxycodone and naloxone
|
RU2004106619A
(ru)
|
2001-08-06 |
2005-07-10 |
Эро-Селтик С.А. (Lu) |
Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
|
US20030044458A1
(en)
|
2001-08-06 |
2003-03-06 |
Curtis Wright |
Oral dosage form comprising a therapeutic agent and an adverse-effect agent
|
WO2003013433A2
(en)
|
2001-08-06 |
2003-02-20 |
Euro-Celtique S.A. |
Sequestered antagonist formulations
|
DE10141650C1
(de)
|
2001-08-24 |
2002-11-28 |
Lohmann Therapie Syst Lts |
Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
|
US20030068276A1
(en)
|
2001-09-17 |
2003-04-10 |
Lyn Hughes |
Dosage forms
|
US20030091635A1
(en)
*
|
2001-09-26 |
2003-05-15 |
Baichwal Anand R. |
Opioid formulations having reduced potential for abuse
|
AU2002340267A1
(en)
*
|
2001-10-19 |
2003-04-28 |
Memorial Sloan-Kettering Cancer Center |
Compositions and methods for reversal of drug resistance
|
US20040033253A1
(en)
*
|
2002-02-19 |
2004-02-19 |
Ihor Shevchuk |
Acyl opioid antagonists
|
US7666876B2
(en)
*
|
2002-03-19 |
2010-02-23 |
Vernalis (R&D) Limited |
Buprenorphine formulations for intranasal delivery
|
EP2308475A1
(en)
|
2002-04-05 |
2011-04-13 |
Euro-Celtique S.A. |
Matrix for sustained, invariant and independent release of active compounds
|
JP2005526839A
(ja)
*
|
2002-04-23 |
2005-09-08 |
アルザ・コーポレーシヨン |
不正使用の可能性が低い経皮鎮痛薬システム
|
WO2003101358A1
(en)
*
|
2002-05-31 |
2003-12-11 |
Titan Pharmaceuticals, Inc. |
Implantable polymeric device for sustained release of buprenorphine
|
AU2003251482A1
(en)
*
|
2002-06-10 |
2003-12-22 |
Euro-Celtique, S.A. |
Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
|
AU2003268144A1
(en)
*
|
2002-08-20 |
2004-03-11 |
Euro-Celtique, S.A. |
Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist
|
AU2003272601B2
(en)
*
|
2002-09-20 |
2009-05-07 |
Alpharma Pharmaceuticals, Llc |
Sustained-release opioid formulations and methods of use
|
US7815934B2
(en)
|
2002-09-20 |
2010-10-19 |
Alpharma Pharmaceuticals, Llc |
Sequestering subunit and related compositions and methods
|
GB0300531D0
(en)
|
2003-01-10 |
2003-02-12 |
West Pharm Serv Drug Res Ltd |
Pharmaceutical compositions
|
CA2518834A1
(en)
*
|
2003-03-13 |
2004-09-30 |
Controlled Chemicals, Inc. |
Oxycodone conjugates with lower the abuse potential and extended duration of action
|
EP1610791B1
(en)
*
|
2003-03-31 |
2011-02-23 |
Titan Pharmaceuticals, Inc. |
Implantable polymeric device for sustained release of dopamine agonist
|
US20040202717A1
(en)
|
2003-04-08 |
2004-10-14 |
Mehta Atul M. |
Abuse-resistant oral dosage forms and method of use thereof
|
TWI347201B
(en)
|
2003-04-21 |
2011-08-21 |
Euro Celtique Sa |
Pharmaceutical products,uses thereof and methods for preparing the same
|
US20040219195A1
(en)
*
|
2003-04-30 |
2004-11-04 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
US8778382B2
(en)
|
2003-04-30 |
2014-07-15 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
US7182955B2
(en)
*
|
2003-04-30 |
2007-02-27 |
3M Innovative Properties Company |
Abuse-resistant transdermal dosage form
|
US8790689B2
(en)
*
|
2003-04-30 |
2014-07-29 |
Purdue Pharma L.P. |
Tamper resistant transdermal dosage form
|
US8906413B2
(en)
*
|
2003-05-12 |
2014-12-09 |
Supernus Pharmaceuticals, Inc. |
Drug formulations having reduced abuse potential
|
US8802139B2
(en)
|
2003-06-26 |
2014-08-12 |
Intellipharmaceutics Corp. |
Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
|
US20080020028A1
(en)
*
|
2003-08-20 |
2008-01-24 |
Euro-Celtique S.A. |
Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
|
US20070191815A1
(en)
|
2004-09-13 |
2007-08-16 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery
|
JP2007527415A
(ja)
*
|
2003-10-30 |
2007-09-27 |
アルザ・コーポレーシヨン |
乱用の可能性が低い経皮鎮痛剤システム
|
US7867511B2
(en)
*
|
2004-01-23 |
2011-01-11 |
Travanti Pharma Inc. |
Abuse potential reduction in abusable substance dosage form
|
US8535711B2
(en)
*
|
2004-01-23 |
2013-09-17 |
Teikoku Pharma Usa, Inc. |
Medication disposal system
|
WO2006079550A2
(en)
*
|
2005-01-28 |
2006-08-03 |
Euro-Celtique S.A. |
Alcohol resistant dosage forms
|
CN1921814B
(zh)
*
|
2004-02-23 |
2012-02-29 |
欧洲凯尔特公司 |
抗滥用阿片样物质透皮递送装置及其制药用途
|
EP1604667A1
(en)
*
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the restless leg syndrome
|
EP1604666A1
(en)
|
2004-06-08 |
2005-12-14 |
Euro-Celtique S.A. |
Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
|
US8394409B2
(en)
|
2004-07-01 |
2013-03-12 |
Intellipharmaceutics Corp. |
Controlled extended drug release technology
|
EP1796651B1
(en)
*
|
2004-08-20 |
2015-05-20 |
3M Innovative Properties Company |
Transdermal drug delivery device with translucent protective film
|
US10624858B2
(en)
|
2004-08-23 |
2020-04-21 |
Intellipharmaceutics Corp |
Controlled release composition using transition coating, and method of preparing same
|
US7226619B1
(en)
|
2004-09-07 |
2007-06-05 |
Pharmorx Inc. |
Material for controlling diversion of medications
|
US8252321B2
(en)
|
2004-09-13 |
2012-08-28 |
Chrono Therapeutics, Inc. |
Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
|
US8541026B2
(en)
|
2004-09-24 |
2013-09-24 |
Abbvie Inc. |
Sustained release formulations of opioid and nonopioid analgesics
|
WO2006044805A2
(en)
*
|
2004-10-15 |
2006-04-27 |
Supernus Pharmaceuticals, Inc. |
Less abusable pharmaceutical preparations
|
US8252320B2
(en)
|
2004-10-21 |
2012-08-28 |
Durect Corporation |
Transdermal delivery system for sufentanil
|
AU2005299738B2
(en)
|
2004-10-21 |
2011-12-01 |
Durect Corporation |
Transdermal delivery systems
|
US7827983B2
(en)
*
|
2004-12-20 |
2010-11-09 |
Hewlett-Packard Development Company, L.P. |
Method for making a pharmaceutically active ingredient abuse-prevention device
|
TW200640526A
(en)
*
|
2005-02-24 |
2006-12-01 |
Alza Corp |
Transdermal electrotransport drug delivery systems with reduced abuse potential
|
EP1702558A1
(en)
|
2005-02-28 |
2006-09-20 |
Euro-Celtique S.A. |
Method and device for the assessment of bowel function
|
EP1695700A1
(en)
*
|
2005-02-28 |
2006-08-30 |
Euro-Celtique S.A. |
Dosage form containing oxycodone and naloxone
|
US20060223786A1
(en)
*
|
2005-04-01 |
2006-10-05 |
Smith David J |
Transdermal pain control method and device
|
DK1895994T3
(da)
*
|
2005-05-13 |
2010-12-20 |
Alza Corp |
Multilagsmedikamentleveringssystem med barriere mod reservoirmaterialeflow
|
CA2629046C
(en)
*
|
2005-12-13 |
2014-04-08 |
Biodelivery Sciences International, Inc. |
Abuse resistant transmucosal drug delivery device
|
US10064828B1
(en)
|
2005-12-23 |
2018-09-04 |
Intellipharmaceutics Corp. |
Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
|
US9289583B2
(en)
|
2006-01-06 |
2016-03-22 |
Acelrx Pharmaceuticals, Inc. |
Methods for administering small volume oral transmucosal dosage forms using a dispensing device
|
US8357114B2
(en)
|
2006-01-06 |
2013-01-22 |
Acelrx Pharmaceuticals, Inc. |
Drug dispensing device with flexible push rod
|
US8865743B2
(en)
|
2006-01-06 |
2014-10-21 |
Acelrx Pharmaceuticals, Inc. |
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
|
US8202535B2
(en)
*
|
2006-01-06 |
2012-06-19 |
Acelrx Pharmaceuticals, Inc. |
Small-volume oral transmucosal dosage forms
|
US8252329B2
(en)
|
2007-01-05 |
2012-08-28 |
Acelrx Pharmaceuticals, Inc. |
Bioadhesive drug formulations for oral transmucosal delivery
|
US9066847B2
(en)
*
|
2007-01-05 |
2015-06-30 |
Aceirx Pharmaceuticals, Inc. |
Storage and dispensing devices for administration of oral transmucosal dosage forms
|
US8252328B2
(en)
*
|
2006-01-06 |
2012-08-28 |
Acelrx Pharmaceuticals, Inc. |
Bioadhesive drug formulations for oral transmucosal delivery
|
US8535714B2
(en)
|
2006-01-06 |
2013-09-17 |
Acelrx Pharmaceuticals, Inc. |
Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
|
US8753308B2
(en)
|
2006-01-06 |
2014-06-17 |
Acelrx Pharmaceuticals, Inc. |
Methods for administering small volume oral transmucosal dosage forms using a dispensing device
|
US7740879B2
(en)
*
|
2006-01-17 |
2010-06-22 |
Harrogate Holdings |
Abuse resistant transdermal drug delivery patch
|
US20070212414A1
(en)
*
|
2006-03-08 |
2007-09-13 |
Penwest Pharmaceuticals Co. |
Ethanol-resistant sustained release formulations
|
JP5457830B2
(ja)
|
2006-04-03 |
2014-04-02 |
オディディ,イサ |
オルガノゾル被膜を含む制御放出送達デバイス
|
US20070248657A1
(en)
*
|
2006-04-25 |
2007-10-25 |
Smith David J |
Multi-compartment transdermal pain control device
|
US20070260491A1
(en)
*
|
2006-05-08 |
2007-11-08 |
Pamela Palmer |
System for delivery and monitoring of administration of controlled substances
|
US10960077B2
(en)
|
2006-05-12 |
2021-03-30 |
Intellipharmaceutics Corp. |
Abuse and alcohol resistant drug composition
|
DE102006025282A1
(de)
|
2006-05-31 |
2007-12-20 |
Lts Lohmann Therapie-Systeme Ag |
Selbstzerstörendes transdermales therapeutisches System
|
US20070278289A1
(en)
*
|
2006-05-31 |
2007-12-06 |
Toshiba Tec Kabushiki Kaisha |
Payment adjusting apparatus and program therefor
|
PL2034975T3
(pl)
|
2006-06-19 |
2012-09-28 |
Alpharma Pharmaceuticals Llc |
Kompozycje farmaceutyczne
|
US20070299687A1
(en)
*
|
2006-06-23 |
2007-12-27 |
Pamela Palmer |
Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
|
EP3566692A1
(en)
|
2006-07-21 |
2019-11-13 |
BioDelivery Sciences International, Inc. |
Transmucosal delivery devices with enhanced uptake
|
EP1897543A1
(en)
|
2006-08-30 |
2008-03-12 |
Euro-Celtique S.A. |
Buprenorphine- wafer for drug substitution therapy
|
US20090124650A1
(en)
*
|
2007-06-21 |
2009-05-14 |
Endo Pharmaceuticals, Inc. |
Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
|
DK2182902T3
(en)
*
|
2007-08-07 |
2015-04-13 |
Acelrx Pharmaceuticals Inc |
Compositions comprising sufentanil and triazolam for procedure sedation and analgesia using oral transmucosal dosage forms
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US9226907B2
(en)
|
2008-02-01 |
2016-01-05 |
Abbvie Inc. |
Extended release hydrocodone acetaminophen and related methods and uses thereof
|
US9700552B2
(en)
|
2008-02-28 |
2017-07-11 |
Syntropharma Limited |
Pharmaceutical compositions for treatment of addiction
|
CA2718943A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Alltranz Inc. |
Abuse deterrent transdermal formulations of opiate agonists and agonist-antagonists
|
DE102008016804B4
(de)
|
2008-04-02 |
2012-01-05 |
Lts Lohmann Therapie-Systeme Ag |
Selbstzerstörendes transdermales therapeutisches System mit verbesserter Funktionalität und Wirksamkeit sowie seine Verwendung
|
EP2293751B1
(en)
*
|
2008-06-23 |
2018-01-10 |
BioDelivery Sciences International, Inc. |
Multidirectional mucosal delivery devices and methods of use
|
US8945592B2
(en)
*
|
2008-11-21 |
2015-02-03 |
Acelrx Pharmaceuticals, Inc. |
Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
|
US20100221313A1
(en)
*
|
2008-12-01 |
2010-09-02 |
Innovative Pharmaceuticals, Llc |
Transdermal reservoir patch
|
PL2405915T3
(pl)
|
2009-03-10 |
2019-05-31 |
Euro Celtique Sa |
Kompozycje farmaceutyczne o natychmiastowym uwalnianiu zawierające oksykodon i nalokson
|
DE102009036485B4
(de)
|
2009-08-07 |
2012-10-04 |
Lts Lohmann Therapie-Systeme Ag |
Mittel zur zerstörenden Entsorgung von medizinischen Wirkstoffen in transdermalen therapeutischen Systemen
|
US20110091544A1
(en)
*
|
2009-10-16 |
2011-04-21 |
Acelrx Pharmaceuticals, Inc. |
Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
|
CA2792878C
(en)
|
2010-03-12 |
2019-10-22 |
Government Of The Usa, As Represented By The Sec., Dept. Of Health And Human Services |
Agonist/antagonist compositions and methods of use
|
CN103491778B
(zh)
|
2010-04-13 |
2017-05-31 |
雷尔玛达治疗股份有限公司 |
1‑甲基‑n‑(2,6‑二甲苯基)‑2‑哌啶甲酰胺的皮肤用药物组合物及其使用方法
|
US20120288551A1
(en)
*
|
2011-05-10 |
2012-11-15 |
Antecip Bioventures Ii Llc |
Implantable Polymeric Device for Sustained Release of Sufentanil
|
WO2013006643A1
(en)
|
2011-07-06 |
2013-01-10 |
The Parkinson's Institute |
Compositions and methods for treatment of symptoms in parkinson's disease patients
|
SG10201610097WA
(en)
|
2011-08-18 |
2017-01-27 |
Biodelivery Sciences Int Inc |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
CA2846956C
(en)
|
2011-09-30 |
2017-12-12 |
Teikoku Pharma Usa, Inc. |
Transdermal patch disposal system
|
US8979724B2
(en)
|
2011-09-30 |
2015-03-17 |
Teikoku Pharma Usa, Inc. |
General medication disposal system
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
MX2016000810A
(es)
|
2013-07-23 |
2016-08-05 |
Euro Celtique Sa |
Combinacion de oxicodona y naloxona para su uso en el tratamiento de dolor en pacientes que sufren de dolor y una enfermedad que resulta la disbiosis intestinal y/o aumento del riesgo de la translocacion bacteriana intestinal.
|
US9132096B1
(en)
|
2014-09-12 |
2015-09-15 |
Alkermes Pharma Ireland Limited |
Abuse resistant pharmaceutical compositions
|
US10010543B1
(en)
|
2014-12-23 |
2018-07-03 |
Barr Laboratories, Inc. |
Transdermal dosage form
|
US10213586B2
(en)
|
2015-01-28 |
2019-02-26 |
Chrono Therapeutics Inc. |
Drug delivery methods and systems
|
AU2016228779A1
(en)
|
2015-03-12 |
2017-09-07 |
Chrono Therapeutics Inc. |
Craving input and support system
|
US11285306B2
(en)
|
2017-01-06 |
2022-03-29 |
Morningside Venture Investments Limited |
Transdermal drug delivery devices and methods
|
US11389844B2
(en)
|
2018-03-20 |
2022-07-19 |
Verde Environmental Technologies, Inc. |
Blister pack disposal system
|
EP3801732A4
(en)
|
2018-05-29 |
2022-04-27 |
Morningside Venture Investments Limited |
DRUG DELIVERY METHODS AND SYSTEMS
|
WO2020009685A1
(en)
|
2018-07-02 |
2020-01-09 |
John Tang |
Transdermal dosage form
|
WO2020008366A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal dosage form
|
WO2020008370A1
(en)
|
2018-07-02 |
2020-01-09 |
Clexio Biosciences Ltd. |
Transdermal patch
|
US11129795B2
(en)
|
2019-02-21 |
2021-09-28 |
Pharmaceutical Productions, Inc. |
Naloxone formulations for sublingual and/or buccal administration
|